Literature DB >> 27913541

What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Maissaa Janbain1, Steven Pipe2.   

Abstract

A 10-year-old boy presents with a history of severe hemophilia A and high-titer inhibitor that had failed high-dose immune tolerance induction (ITI) with a recombinant factor VIII (rFVIII) product and a plasma-derived FVIII product. You are asked by his mother whether he should be tried on ITI with an extended half-life product, in particular, consideration of a rFVIIIFc concentrate.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27913541      PMCID： PMC6142440          DOI： 10.1182/asheducation-2016.1.648

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  10 in total

Review 1.  Immunogenicity of long-lasting recombinant factor VIII products.

Authors:  Mathieu Ing; Nimesh Gupta; Maud Teyssandier; Bernard Maillère; Marc Pallardy; Sandrine Delignat; Sébastien Lacroix-Desmazes
Journal:  Cell Immunol       Date:  2015-12-19       Impact factor: 4.868

2.  Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

Authors:  G Young; J Mahlangu; R Kulkarni; B Nolan; R Liesner; J Pasi; C Barnes; S Neelakantan; G Gambino; L M Cristiano; G F Pierce; G Allen
Journal:  J Thromb Haemost       Date:  2015-04-23       Impact factor: 5.824

3.  Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.

Authors:  Charles L Groomes; David M Gianferante; Gary D Crouch; Dina S Parekh; David W Scott; Kenneth Lieuw
Journal:  Pediatr Blood Cancer       Date:  2016-01-06       Impact factor: 3.167

Review 4.  FcRn: the neonatal Fc receptor comes of age.

Authors:  Derry C Roopenian; Shreeram Akilesh
Journal:  Nat Rev Immunol       Date:  2007-08-17       Impact factor: 53.106

Review 5.  New predictive approaches for ITI treatment.

Authors:  G D Minno; E Santagostino; K Pratt; C Königs
Journal:  Haemophilia       Date:  2014-09       Impact factor: 4.287

Review 6.  ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.

Authors:  J Oldenburg; S K Austin; C M Kessler
Journal:  Haemophilia       Date:  2014-09       Impact factor: 4.287

Review 7.  Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review.

Authors:  Alice S van Velzen; Marjolein Peters; Johanna G van der Bom; Karin Fijnvandraat
Journal:  Br J Haematol       Date:  2014-05-16       Impact factor: 6.998

8.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

Authors:  Johnny Mahlangu; Jerry S Powell; Margaret V Ragni; Pratima Chowdary; Neil C Josephson; Ingrid Pabinger; Hideji Hanabusa; Naresh Gupta; Roshni Kulkarni; Patrick Fogarty; David Perry; Amy Shapiro; K John Pasi; Shashikant Apte; Ivan Nestorov; Haiyan Jiang; Shuanglian Li; Srividya Neelakantan; Lynda M Cristiano; Jaya Goyal; Jurg M Sommer; Jennifer A Dumont; Nigel Dodd; Karen Nugent; Gloria Vigliani; Alvin Luk; Aoife Brennan; Glenn F Pierce
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

Review 9.  Tregitope peptides: the active pharmaceutical ingredient of IVIG?

Authors:  Anne S De Groot; Leslie Cousens; Federico Mingozzi; William Martin
Journal:  Clin Dev Immunol       Date:  2013-12-25

10.  Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.

Authors:  Sriram Krishnamoorthy; Tongyao Liu; Douglas Drager; Susannah Patarroyo-White; Ekta Seth Chhabra; Robert Peters; Neil Josephson; David Lillicrap; Richard S Blumberg; Glenn F Pierce; Haiyan Jiang
Journal:  Cell Immunol       Date:  2015-12-29       Impact factor: 4.868
  10 in total
  3 in total

1.  Evolution of Hemophilia Care in India.

Authors:  Kanjaksha Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2018-12-19       Impact factor: 0.900

2.  Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.

Authors:  Mohsen Elalfy; Islam Elghamry; Hoda Hassab; Omar Elalfy; Nevine Andrawes; Magdy El-Ekiaby
Journal:  Haemophilia       Date:  2021-11-19       Impact factor: 4.263

Review 3.  Recombinant factor VIII Fc for the treatment of haemophilia A.

Authors:  Cedric Hermans; Maria Elisa Mancuso; Beatrice Nolan; K John Pasi
Journal:  Eur J Haematol       Date:  2021-03-31       Impact factor: 2.997
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.